Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
13,876,978
-
Shares change
-
+119,967
-
Total reported value, excl. options
-
$18,039,320
-
Value change
-
+$23,111
-
Put/Call ratio
-
200%
-
Number of buys
-
17
-
Number of sells
-
-19
-
Price
-
$1.30
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q2 2024
61 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,876,978 shares
of 55,705,828 outstanding shares and own 25% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (3,750,450 shares), VANGUARD GROUP INC (1,770,525 shares), ACADIAN ASSET MANAGEMENT LLC (1,071,860 shares), RENAISSANCE TECHNOLOGIES LLC (975,952 shares), ADAR1 Capital Management, LLC (918,929 shares), Alphabet Inc. (889,979 shares), Murchinson Ltd. (873,910 shares), Atlas Venture Life Science Advisors, LLC (535,336 shares), GEODE CAPITAL MANAGEMENT, LLC (492,187 shares), and BlackRock Inc. (483,402 shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.